The Hows and the Whys of Diagnosing Gastroesophageal Reflux Disease in 2022
DOI:
https://doi.org/10.52787/agl.v52i2.215Keywords:
Gastroesophageal reflux disease, erosive esophagitis, acid exposure timeAbstract
Gastroesophageal reflux disease (GERD) is very common in the population, with reported prevalence rates of between 10 and 30%, both in Latin America1 and the rest of the world.2 This, coupled with the fact that diagnosis usually requires costly studies and management involves prolonged medical treatment or surgery, makes GERD an enormous economic burden for countries.3 On the other hand, it has a significant impact on quality of life, with reports of worse quality of life than in cases of diseases such as angina pectoris or heart failure.4 In this context, a cost-effective diagnostic, and therapeutic approach is essential, especially in underdeveloped countries.
Technological advances in recent years have led to new diagnostic methods and new variables for the diagnosis of GERD. As a result, it has been necessary to develop several consensus documents and update management guidelines,5-7 including the recently developed Latin American Consensus 2022. Among these, the Lyon Consensus stands out, which was published in 2018 and is the fruit of years of work by a group of renowned world experts.8 It has been tremendously influential as it has redefined the diagnostic criteria for GERD. These definitions have been adopted, for example, by the Latin American Consensus, and this document is based on them.
References
-1. Salis G. Systematic review: Epidemiology of gastroesophageal reflux disease in Latin America. Acta Gastroenterol Latinoam 2011;41:60-9.
-2. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014;63:871-80.
-3. Peery AF, Crockett SD, Murphy CC, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. Gastroenterology 2022;162:621-644.
-4. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22:108-14.
-5. Jung HK, Tae CH, Song KH, et al. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:453-481.
-6. Yadlapati R, Gyawali CP, Pandolfino JE. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol 2022;20:984-994.e1.
-7. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Official journal of the American College of Gastroenterology | ACG 2022;117:27-56.
-8. Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018;67:1351-1362.
-9. Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken) 2015;67:891-7.
-10. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol 2017;960:1-17.
-11. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-81.
-12. Bove M, Ruth M, Cange L, et al. 24-H pharyngeal pH monitoring in healthy volunteers: a normative study. Scand J Gastroenterol 2000;35:234-41.
-13. Sifrim D, Roman S, Savarino E, et al. Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. Gut 2020.
-14. Fujiwara Y, Higuchi K, Watanabe Y, et al. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol 2005;20:26-9.
-15. Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population--the Kalixanda study. Aliment Pharmacol Ther 2006;23:1725-33.
-16. Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001;120:1588-98.
-17. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006;55:313-8.
-18. Hoff DAL, McMahon B, Gregersen H. Esophageal multimodal stimulation and sensation. Ann N Y Acad Sci 2018;1434:210-218.
-19. Ustaoglu A, Woodland P. Esophageal afferent innervation and its role in gastro-esophageal reflux disease symptoms. Curr Opin Gastroenterol 2021;37:372-377.
-20. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20; quiz 1943.
-21. Lacy BE, Weiser K, Chertoff J, et al. The diagnosis of gastroesophageal reflux disease. Am J Med 2010;123:583-92.
-22. Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004;140:518-27.
-23. Numans ME, de Wit NJ. Reflux symptoms in general practice: diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionnaire. Aliment Pharmacol Ther 2003;17:1049-55.
-24. Bhatia SJ, Makharia GK, Abraham P, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol 2019;38:411-440.
-25. Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol 2013;10:371-80.
-26. Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010;71:28-34.
-27. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7.
-28. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.
-29. Akdamar K, Ertan A, Agrawal NM, et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc 1986;32:78-80.
-30. Takashima T, Iwakiri R, Sakata Y, et al. Endoscopic reflux esophagitis and Helicobacter pylori infection in young healthy Japanese volunteers. Digestion 2012;86:55-8.
-31. Nasseri-Moghaddam S, Razjouyan H, Nouraei M, et al. Inter- and intra-observer variability of the Los Angeles classification: a reassessment. Arch Iran Med 2007;10:48-53.
-32. Pandolfino JE, Vakil NB, Kahrilas PJ. Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. Gastrointest Endosc 2002;56:639-43.
-33. Savarino E, de Bortoli N, De Cassan C, et al. The natural history of gastroesophageal reflux disease: a comprehensive review. Dis Esophagus 2017;30:1-9.
-34. Wiener GJ, Morgan TM, Copper JB, et al. Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 1988;33:1127-33.
-35. de Bortoli N, Martinucci I, Savarino E, et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil 2014;26:28-35.
-36. Wang AJ, Wang H, Xu L, et al. Predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease. Dig Liver Dis 2013;45:296-300.
-37. Ribolsi M, Savarino E, De Bortoli N, et al. Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. Aliment Pharmacol Ther 2014;40:966-73.
-38. Francis DO, Goutte M, Slaughter JC, et al. Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux. Laryngoscope 2011;121:1902-9.
-39. Patel A, Sayuk GS, Gyawali CP. Acid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters. Am J Gastroenterol 2014;109:836-44.
-40. Patel A, Sayuk GS, Gyawali CP. Parameters on esophageal pH-impedance monitoring that predict outcomes of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2015;13:884-91.
-41. Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastroesophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017;29:1-15.
-42. Smout AJ, Breedijk M, van der Zouw C, et al. Physiological gastroesophageal reflux and esophageal motor activity studied with a new system for 24-hour recording and automated analysis. Dig Dis Sci 1989;34:372-8.
-43. Richter JE, Bradley LA, DeMeester TR, et al. Normal 24-hr ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci 1992;37:849-56.
-44. Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005;22:1011-21.
-45. Rengarajan A, Savarino E, Della Coletta M, et al. Mean Nocturnal Baseline Impedance Correlates With Symptom Outcome When Acid Exposure Time Is Inconclusive on Esophageal Reflux Monitoring. Clin Gastroenterol Hepatol 2020;18:589-595.
-46. Patel A, Wang D, Sainani N, et al. Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2016;44:890-8.
-47. Ribolsi M, Frazzoni M, Marabotto E, et al. Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus. Aliment Pharmacol Ther 2021;54:412-418.
-48. Gyawali CP, Tutuian R, Zerbib F, et al. Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management. Gastroenterology 2021;161:1412-1422.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Daniel Cisternas
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
